Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report was filed by Mobia Medical, Inc. on July 14, 2026. The filing reports a corporate governance event involving the Board of Directors.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.

Material Changes

  • Board Expansion: The Board of Directors increased its size from six to seven members.
  • New Appointment: Reza Zadno, Ph.D., was appointed as a new Class III director, with a term expiring at the 2029 annual meeting.
  • Committee Assignment: Dr. Zadno was appointed to the Compensation Committee. Consequently, Dr. William Harrington resigned from the Compensation Committee.
  • Committee Composition: The Compensation Committee now consists of Casey Tansey (Chair), Dana Mead, and Dr. Zadno.

Outlook, Commentary, and Risks

Management Commentary: The Board determined that Dr. Zadno qualifies as an independent director and satisfies Nasdaq listing standards for the Compensation Committee. Dr. Zadno brings significant experience, having previously served as CEO of PROCEPT BioRobotics Corporation (2020–2025) and Avedro, Inc. (2016–2020).

Compensation and Agreements: Dr. Zadno will receive compensation as a non-employee director in accordance with the company's standard program. Mobia expects to enter into a standard indemnification agreement with him.

Risks and Contingencies: The filing states there are no transactions between Dr. Zadno and Mobia requiring reporting under Item 404(a) of Regulation S-K, and no arrangements exist regarding his selection as a director.

Key Facts for Investor Verification

  • Verify Dr. Zadno's independence status and specific qualifications for the Compensation Committee under current Nasdaq rules.
  • Review the specific terms of the non-employee director compensation program applicable to Dr. Zadno.
  • Confirm the execution of the standard indemnification agreement with the new director.
  • Monitor the impact of the new board composition on future strategic decisions, particularly given Dr. Zadno's background in surgical robotics and ophthalmology.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.